Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study DOI Creative Commons

N Osawa,

Kenro Chikazawa, Ken Imai

et al.

Journal of Gynecologic Oncology, Journal Year: 2024, Volume and Issue: 36

Published: Nov. 19, 2024

This study aimed to evaluate the oncological safety of laparoscopic surgery for patients with benign tumors who underwent at our facility and were subsequently diagnosed borderline ovarian or cancer. We conducted a retrospective review 45 initially institution from January 2009 April 2024. Postoperative pathological examination identified 32 cases 13 Laparoscopic cystectomy was performed in 14 (43.8%) 4 (30.8%) cancer cases. Out cystectomy, 8 staging laparotomy, whereas 6 only tumor cystectomy. In contrast, none completed treatment Recurrent disease observed 9.4% cases, all which successfully managed further surgery. group, recurrence occurred 31% patients, 3 resulting tumor-related mortality. is suggested be oncologically safe, low rate no adverse impact on survival. However, cancer, particularly peritoneal dissemination, rapid progression remains concern. While this suggests that may viable option tumors, research needed validate these findings,

Language: Английский

Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021 DOI Creative Commons
Tianye Li, Haoxiang Zhang,

Mengyi Lian

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 10, 2025

Female-specific cancers, particularly breast, cervical, ovarian, and uterine account for nearly 40% of all cancers in women. This study aimed to analyze the global epidemiological trends these from 1990 2021, offering insights into their evolving patterns providing valuable information health policymakers allocate healthcare resources more effectively. Data Global Burden Disease Study 2021 (GBD 2021) were used comprehensively assess incidence, mortality, disability-adjusted life years (DALYs) female-specific cancers. Age-standardized rates facilitated cross-regional comparisons, accounting differences population size demographics. The socio-demographic index (SDI) was employed categorize regions evaluate correlations between cancer burden economic level. In addition, risk factors attributable deaths DALYs assessed based on comparative assessment model GBD project. From increased at varying rates. breast accounted 2.08 million incident cases, 0.66 deaths, 20.25 globally. comparison, had lower burdens, with 0.67 million, 0.30 0.47 respectively. showed positive SDI, while cervical exhibited a negative correlation. Attributable cancer-associated included dietary risks, high body-mass (BMI), fasting plasma glucose, alcohol use, tobacco low physical activity. Additional unsafe sex use cancer, BMI occupational risks ovarian cancer. has recent decades, significant demographic regional discrepancies. These findings highlight urgent need targeted public interventions mitigate impact

Language: Английский

Citations

5
IER5 Promotes Ovarian Cancer Cell Proliferation and Peritoneal Dissemination DOI Open Access
Jayaraman Krishnaraj, Sayaka Ueno, Masato Nakamura

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 610 - 610

Published: Feb. 11, 2025

Background/Objective: Ovarian cancer (OC) is one of the most lethal gynecological cancers, having a worldwide mortality rate 66% in 2020. The overall 5-year relative survival only 21% for distant stages, due to lack early diagnosis. Epithelial OC, common high-grade serous carcinoma, carries p53 mutations cases. However, we found that immediate response 5 gene (IER5), target gene, overexpressed ovarian cells. molecular mechanism underlying role IER5 OC has not been well studied. We previously reported promotes dephosphorylation and activation heat shock factor-1 (HSF1), master regulator proteostasis, which induces protein (HSP) expression. Methods/Results: Here show Ier5 mRNA expression higher cells (MOV, ID8G, HM-1) compared normal also floating ascites have than parental strain. Knockdown suppressed HSP upregulation proliferation while overexpression promoted upregulation. Hsf1 showed results similar knockdown. Conclusions: These indicate IER5-HSF1 pathway contributes peritoneal dissemination family genes related poorer prognosis patients, suggesting potential as diagnostic markers therapeutic targets.

Language: Английский

Citations

0
Past and present: a bibliometric study on the treatment of recurrent ovarian cancer DOI Creative Commons

Xiao-yuan Hao,

Wen-wei Song,

Miaoling Li

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 30, 2024

Ovarian cancer (OC) is a gynecological malignancy with high mortality rate worldwide. The unfavorable prognosis of OC mainly attributed to the recurrent propensity. Recently, from has exhibited downward trend. These favorable patterns are likely be driven by advancements in novel therapeutic regimens. However, there lack visualize analysis application these new drugs on women (ROC). Therefore, we aimed provide bibliometric evolving paradigms ROC treatment.

Language: Английский

Citations

1
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer DOI
Mika Okazawa‐Sakai, Shunsuke A. Sakai, Ichinosuke Hyodo

et al.

Journal of Gynecologic Oncology, Journal Year: 2024, Volume and Issue: 36

Published: Oct. 23, 2024

To investigate an association between the gut microbiome and efficacy of poly(ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer.

Language: Английский

Citations

0
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps DOI Open Access
Kyung‐Jin Min,

Nam Kyeong Kim,

Jae Yun Song

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3422 - 3422

Published: Oct. 9, 2024

The Korean Gynecologic Oncology Group (KGOG) was established in 2002 and is the only organization Korea conducting multi-center clinical trials for gynecologic cancers. Since its re-establishment as a non-profit 2021, KGOG has grown significantly, now including 207 oncology specialists from 76 hospitals. This growth testament to dedication hard work of all those involved organization. committed maximizing activation research through policies that support patients with rare diseases cancer research, focusing on strengthening institutional capacity, equalizing participation opportunities, enhancing information sharing. A significant milestone becoming member US (GOG) 2005, allowing GOG trials. later joined Cancer InterGroup (GCIG) strengthened capabilities by hosting first Endometrial Consensus Conference—Clinical Research (ECCC-CR) 2023. holds biannual meetings symposia, well 224 operating committee annually review discussions Tumor Site Committee. conducted 156 investigator-initiated trial (IIT) or sponsor-initiated (SIT) studies KGOG-led participated research. Currently, 18 are registered, 10 preparation. To date, 68 papers have been published. conducts six national projects collaborates external organizations such NRG Foundation, Partners (GOG-P), GCIG, East Asian Trial group (EAGOT), Japanese (JGOG). Through collaboration renowned international institutions, significantly expanded scope achieving noteworthy outcomes. report not introduces history recent status but also presents exciting future direction organization, filled potential breakthroughs advancements

Language: Английский

Citations

0
Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study DOI Creative Commons

N Osawa,

Kenro Chikazawa, Ken Imai

et al.

Journal of Gynecologic Oncology, Journal Year: 2024, Volume and Issue: 36

Published: Nov. 19, 2024

This study aimed to evaluate the oncological safety of laparoscopic surgery for patients with benign tumors who underwent at our facility and were subsequently diagnosed borderline ovarian or cancer. We conducted a retrospective review 45 initially institution from January 2009 April 2024. Postoperative pathological examination identified 32 cases 13 Laparoscopic cystectomy was performed in 14 (43.8%) 4 (30.8%) cancer cases. Out cystectomy, 8 staging laparotomy, whereas 6 only tumor cystectomy. In contrast, none completed treatment Recurrent disease observed 9.4% cases, all which successfully managed further surgery. group, recurrence occurred 31% patients, 3 resulting tumor-related mortality. is suggested be oncologically safe, low rate no adverse impact on survival. However, cancer, particularly peritoneal dissemination, rapid progression remains concern. While this suggests that may viable option tumors, research needed validate these findings,

Language: Английский

Citations

0